Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - john+chute
3
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
2016-518: Inhibition of Protein Tyrosine Phosphatase-Sigma for Hematopoietic Regeneration
Inhibition Of Protein Tyrosine Phosphatase - Sigma For Hematopoietic RegenerationSUMMARYUCLA Researchers have identified a novel pharmacological target for hematopoietic stem cell regeneration. They have developed small molecule inhibitors against the target and shown that the inhibitors cause rapid stem cell regeneration.BACKGROUNDDepletion of white...
Published: 7/19/2023
|
Inventor(s):
John Chute
,
Michael Jung
,
Emelyne Diers
Keywords(s):
Autoimmune
,
Hematology
,
Inflammatory Diseases
,
iPS/stem cells
,
Oncology
Category(s):
Therapeutics > Autoimmune
,
Therapeutics > Oncology
,
Therapeutics > Hematology
,
Therapeutics > Inflammation And Inflammatory Diseases
,
Therapeutics > Stem Cells And Regenerative Medicine > Ips Stem Cells
2015-365 TARGETING PROTEIN TYROSINE PHOSPHATASE-SIGMA TO AUGMENT HEMATOPOIETIC RECONSTITUTION
Targeting Protein Tyrosine Phosphatase-Sigma to Augment Hematopoietic ReconstitutionSUMMARYUCLA researchers from the Department of Medicine have developed a novel technique for inducing increased hematopoietic recovery after HSC transplantation by targeting the protein tyrosine phosphatase-sigma (PTP-sigma) pathway.BACKGROUNDReceptor tyrosine kinases...
Published: 7/19/2023
|
Inventor(s):
John Chute
Keywords(s):
Hematology
,
Life Science Research Tools
,
Targets And Assays
,
Therapeutics & Vaccines
Category(s):
Life Science Research Tools
,
Diagnostic Markers > Targets And Assays
,
Therapeutics
,
Therapeutics > Hematology
Targeted Inhibition of Human Multiple Myeloma
Case 2018-175UCLA researchers in the Department of Medicine have discovered a novel mechanism involving Eph receptor/ephrin ligand interaction, that regulates human multiple myeloma growth and repopulation in vivo.BACKGROUNDMultiple myeloma (MM) is a plasma cell malignancy often accompanied by bone osteolytic lesions. Despite standard care with high...
Published: 7/19/2023
|
Inventor(s):
John Chute
,
Joshua Sasine
Keywords(s):
Hematology
,
Therapeutics & Vaccines
Category(s):
Therapeutics
,
Therapeutics > Hematology